Polen Capital's position in Lilly(Eli) & is currently worth $436 Million. That's 1.00% of their equity portfolio (22nd largest holding). Polen Capital started to build up the position in Lilly(Eli) & in Q3 2023. Since then they sold 29 Thousand shares. The stake costed the investor $306 Million, netting the investor a gain of 42% so far.
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis supp...
Benzinga, about 1 month ago… stock. Eli Lilly and Company Stock Performance Shares of Eli Lilly and Company … insiders. Eli Lilly and Company Company Profile (Free Report) Eli Lilly an...
EIN News Pharmaceuticals, 4 months ago… company’s stock. Eli Lilly and Company Stock Performance Eli Lilly and Company stock … s stock. Eli Lilly and Company Profile (Free Report) Eli Lilly and C...
EIN News Pharmaceuticals, 5 months agoThe hunt for the next trillion-dollar companies invariably ignites investor excitement. Moreover, the AI-led excitement in equities this year pushed tech sto...
InvestorPlace, 6 months ago